Pular para o conteúdo principal
Ranking Invest

CABA - Cabaletta Bio, Inc.

Segmento: HealthcareCabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Análise Ranking Invest

Valor de Mercado
$ 257.71 Mi
IVR
-0.81Índice proprietário de comparação relativa: -0,81.
IVR2
-1.71Leitura proprietária complementar: -171%.
MLL
-1.71Leitura proprietária complementar: -171%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 210.59 Mi

Dívida Líquida

-$ 225.10 Mi

L4T

-$ 181.32 Mi

Indicadores Básicos

ROE

-86.10%

Índices de Previsibilidade

Receita Líquida

A0.00

Lucro

A0.09

Margem

A0.00

Índices de Tendência

Receita Líquida

D0.00

Lucro

G-11.62

Margem

D0.00

Índices de Endividamento

DIV/PAT

-1.07

DIV/L4T

1.24

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.